Search For "sii"
Amazed at how much PM Modi knew, says SII's Adar Poonawalla
Updated : 4 months, 3 weeks ago IST
Pune (Maharashtra) [India], November 28 (ANI): Hours after Prime Minister Narendra Modi visited Pune-based Serum Institute of India (SII), its Chief Executive Officer Adar Poonawalla said that he was amazed by the Prime Minister's knowledge about vaccines and vaccine production.
Read More
Centre may purchase 300-400 million Covishield doses by July 2021:
Updated : 4 months, 3 weeks ago IST
New Delhi [India], November 28 (ANI): After Prime Minister Narendra Modi visited the company's pandemic level facility in Pune, Serum Institute of India's (SII), Chief Executive Officer (CEO) Adar Poonawalla on Saturday said that indications suggest that the central government may purchase 3
Read More
Preparations underway at Serum Institute of India ahead of PM Modi
Updated : 4 months, 3 weeks ago IST
Pune (Maharashtra) [India], November 27 (ANI): Preparations are underway at Serum Institute of India (SII) where Prime Minister Narendra Modi is expected to visit on November 28 to review the COVID-19 vaccine production and its distribution mechanisms.
Read More
Will have to wait for final words in scientific journal: CSIR chie
Updated : 4 months, 3 weeks ago IST
New Delhi [India], November 25 (ANI): A day after Serum Institute of India (SII) Chief Executive Officer Adar Poonawalla asserted that its "soon to be widely available COVID-19 vaccine will offer protection up to 90 per cent in one type of dosage regime", Council of Scientific and Industrial
Read More
Serum Institute of India CEO expresses delight at Covishield vacci
Updated : 4 months, 3 weeks ago IST
New Delhi [India], November 23 (ANI): Serum Institute of India (SII), CEO, Adar Poonawalla on Monday said that he is delighted to hear that Covidshield, soon to be widely available COVID-19 vaccine, will offer protection up to 90 per cent in one dosage regime and 62 per cent in another.
Read More
Oxford University Covid-19 vaccine "well tolerated in older adults
Updated : 5 months ago IST
New Delhi [India], November 19 (ANI): Major drug marker Serum of Institute of India (SII) on Thursday said that the coronavirus vaccine, developed by teams at the University of Oxford, has been shown to trigger a robust immune response in healthy adults aged 56-69 and those over 70 years
Read More
COVISHIELD completes enrolment of Phase III clinical trials under
Updated : 5 months, 1 week ago IST
New Delhi [India], November 12 (ANI): The Serum Institute of India (SII) and Indian Council of Medical Research (ICMR) have announced the completion of enrolment of phase 3 clinical trials for COVISHIELD in India.
Read More
Serum Institute of India to produce additional 100 million COVID-1
Updated : 6 months, 3 weeks ago IST
Pune (Maharashtra) [India], September 29 (ANI): Serum Institute of India (SII) will produce up to an additional 100 million COVID-19 vaccine doses for India and low and middle-income countries (LMICs) in 2021.
Read More
Serum Institute all set to begin phase 3 trials of Covid-19 vaccin
Updated : 7 months ago IST
Pune (Maharashtra) [India], September 19 (ANI): Serum Institute of India (SII) is all set to begin phase three trials of the Covishield Vaccine developed by AstraZeneca and Oxford University at Sassoon General Hospital in Pune, the hospital administration said on Saturday.
Read More
DCGI gives nod to Serum Institute to restart phase 2,3 trials for
Updated : 7 months ago IST
New Delhi [India], September 16 (ANI): The Drugs Controller General of India (DCGI) has allowed Serum Institute of India (SII) to restart its phase two and three clinical trials for COVID-19 vaccine after the pharma major submitted the recommendations of the Data Safety Monitoring Board (DSM
Read More
Serum Institute to resume COVID-19 vaccine trials in India after D
Updated : 7 months, 1 week ago IST
New Delhi [India], September 12 (ANI): Hours after clinical trials for AstraZeneca and Oxford University coronavirus vaccine resumed on Saturday in the UK, pharma major Serum Institute of India (SII) said it will resume the trials in India once Drugs Controller General of India (DCGI) gives
Read More
DCGI directs Serum Institute to suspend any new recruitment in pha
Updated : 7 months, 1 week ago IST
New Delhi [India], September 12 (ANI): The Drugs Controller General of India (DCGI) Dr VG Somani on Friday ordered the pharma giant Serum Institute of India (SII) to suspend any new recruitment in phase 2 and 3 clinical trials for COVID-19 vaccine till further orders.
Read More